Bioavailable 25(OH)D level is associated with clinical outcomes of patients with diffuse large B-cell lymphoma: An exploratory study

  • Author Footnotes
    1 These authors contributed equally to the study.
    Peizhan Chen
    Footnotes
    1 These authors contributed equally to the study.
    Affiliations
    State Key Laboratory of Oncogenes and Related Genes, Center for Single-Cell Omics, School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai 20025, PR China
    Search for articles by this author
  • Author Footnotes
    1 These authors contributed equally to the study.
    Yiwen Cao
    Footnotes
    1 These authors contributed equally to the study.
    Affiliations
    State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
    Search for articles by this author
  • Xiaohua Duan
    Affiliations
    State Key Laboratory of Oncogenes and Related Genes, Center for Single-Cell Omics, School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai 20025, PR China
    Search for articles by this author
  • Jingquan Li
    Affiliations
    State Key Laboratory of Oncogenes and Related Genes, Center for Single-Cell Omics, School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai 20025, PR China
    Search for articles by this author
  • Weili Zhao
    Correspondence
    Corresponding author. State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 197 Ruijin second road, Shanghai 200025, PR China. Fax: +86 21-64743206.
    Affiliations
    State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China

    Pôle de Recherches Sino-Françaisen Science Du Vivant et Génomique, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
    Search for articles by this author
  • Hui Wang
    Correspondence
    Corresponding author. School of public health, Shanghai Jiao tong University School of Medicine, 227 South Chongqing Road, Shanghai 200025, PR China. Fax: +86 21-63850472.
    Affiliations
    State Key Laboratory of Oncogenes and Related Genes, Center for Single-Cell Omics, School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai 20025, PR China

    CAS Key Laboratory of Nutrition, Metabolism and Food Safety, Shanghai Institute of Nutrition and Health, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai 200031, China
    Search for articles by this author
  • Author Footnotes
    1 These authors contributed equally to the study.

      Highlights

      • DLBCL patients with higher bioavailable 25(OH)D level are associated with better prognosis.
      • Blood 25(OH)D levels are negatively correlated with IPI factors in DLBCL patients.
      • DLBCL patients with higher blood 25(OH)D levels are more sensitive to R–CHOP treatments.

      Summary

      Backgrounds & aims

      Vitamin D insufficiency is associated with worse clinical outcomes in multiple cancer types; however, its roles in diffuse large B-cell lymphoma (DLBCL) patients are still unclear. Here, we aimed to determine the prognostic values of circulating total 25(OH)D and bioavailable 25(OH)D levels in DLBCL patients.

      Methods

      A total of 332 newly diagnosed DLBCL patients were recruited. The plasma total 25(OH)D and bioavailable 25(OH)D levels at diagnosis were determined, and their associations with the clinical characteristics and the prognosis of patients were evaluated. The predictive values of clinical characteristics and 25(OH)D levels in the responses to R–CHOP treatments in DLBCL patients were also assessed.

      Results

      Of the patients, 92.8% had insufficient vitamin D status (<30 ng/mL). Patients with higher plasma bioavailable 25(OH)D were associated with better progression-free survival (PFS, multivariate adjusted-HR = 0.72, 95% CI = 0.38–1.35, P = 0.301, Tertile 2 vs. 1; multivariate adjusted-HR = 0.39, 95% CI = 0.20–0.79, P = 0.009, Tertile 3 vs. 1) and overall survival (OS, multivariate adjusted-HR = 0.89, 95% CI = 0.39–2.02, P = 0.777, Tertile 2 vs. 1; multivariate adjusted-HR = 0.21, 95% CI = 0.07–0.65, P = 0.007, Tertile 3 vs. 1). Meanwhile, higher plasma total 25(OH)D level was significantly associated with better PFS but not OS in DLBCL patients. Besides, DLBCL patients with higher total or bioavailable 25(OH)D levels were more sensitive to the R–CHOP regimen treatments.

      Conclusion

      The bioavailable 25(OH)D level may serve as a novel prognostic biomarker in DLBCL patients.

      Keywords

      To read this article in full you will need to make a payment
      Subscribe to Clinical Nutrition
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Gordon L.I.
        • Harrington D.
        • Andersen J.
        • Colgan J.
        • Glick J.
        • Neiman R.
        • et al.
        Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma.
        N Engl J Med. 1992; 327: 1342
        • Czuczman M.S.
        • Grillo-López A.J.
        • White C.A.
        • Saleh M.
        • Gordon L.
        • Lobuglio A.F.
        • et al.
        Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy.
        J Clin Oncol. 1999; 17: 268-276
        • Zhang J.
        • Grubor V.
        • Love C.L.
        • Banerjee A.
        • Richards K.L.
        • Mieczkowski P.A.
        • et al.
        Genetic heterogeneity of diffuse large B-cell lymphoma.
        Proc Natl Acad Sci U S A. 2013; 110: 1398-1403
        • Coiffier B.
        • Thieblemont C.
        • Van Den Neste E.
        • Lepeu G.
        • Plantier I.
        • Castaigne S.
        • et al.
        Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte.
        Blood. 2010; 116: 2040-2045
        • Raut L.S.
        • Chakrabarti P.P.
        Management of relapsed-refractory diffuse large B cell lymphoma.
        S Asian J Canc. 2014; 3: 66-70
        • Larrabeiti-Etxebarria A.
        • Lopez-Santillan M.
        • Santos-Zorrozua B.
        • Lopez-Lopez E.
        • Garcia-Orad A.
        Systematic review of the potential of MicroRNAs in diffuse large B cell lymphoma.
        Cancers. 2019; 11: E144
        • Chen P.Z.
        • Li M.
        • Duan X.H.
        • Jia J.Y.
        • Li J.Q.
        • Chu R.A.
        • et al.
        Pharmacokinetics and effects of demographic factors on blood 25(OH)D3 levels after a single orally administered high dose of vitamin D3.
        Acta Pharmacol Sin. 2016; 37: 1509-1515
        • Li C.
        • Chen P.
        • Duan X.
        • Wang J.
        • Shu B.
        • Li X.
        • et al.
        Bioavailable 25(OH)D but not total 25(OH)D is an independent determinant for bone mineral density in Chinese postmenopausal women.
        EBioMedicine. 2017; 15: 184-192
        • Feldman D.
        • Krishnan A.V.
        • Swami S.
        • Giovannucci E.
        • Feldman B.J.
        The role of vitamin D in reducing cancer risk and progression.
        Nat Rev Canc. 2014; 14: 342-357
        • Powe C.E.
        • Evans M.K.
        • Wenger J.
        • Zonderman A.B.
        • Berg A.H.
        • Nalls M.
        • et al.
        Vitamin D-binding protein and vitamin D status of black Americans and white Americans.
        N Engl J Med. 2013; 369: 1991-2000
        • Kim H.Y.
        • Kim J.H.
        • Jung M.H.
        • Cho I.A.
        • Kim Y.
        • Cho M.C.
        Clinical usefulness of bioavailable vitamin D and impact of GC genotyping on the determination of bioavailable vitamin D in a Korean population.
        Internet J Endocrinol. 2019; 2019: 9120467
        • Pelczynska M.
        • Grzelak T.
        • Sperling M.
        • Bogdanski P.
        • Pupek-Musialik D.
        • Czyzewska K.
        Impact of 25-hydroxyvitamin D, free and bioavailable fractions of vitamin D, and vitamin D binding protein levels on metabolic syndrome components.
        Arch Med Sci. 2017; 13: 745-752
        • Yu C.
        • Xue H.
        • Wang L.
        • Chen Q.
        • Chen X.
        • Zhang Y.
        • et al.
        Serum bioavailable and free 25-hydroxyvitamin D levels, but not its total level, are associated with the risk of mortality in patients with coronary artery disease.
        Circ Res. 2018; 123: 996-1007
        • Peris P.
        • Filella X.
        • Monegal A.
        • Guanabens N.
        • Foj L.
        • Bonet M.
        • et al.
        Comparison of total, free and bioavailable 25-OH vitamin D determinations to evaluate its biological activity in healthy adults: the LabOscat study.
        Osteoporos Int. 2017; 28: 2457-2464
        • Thambiah S.C.
        • Wong T.H.
        • Gupta E.D.
        • Radhakrishnan A.K.
        • Gun S.C.
        • Chembalingam G.
        • et al.
        Calculation of free and bioavailable vitamin D and its association with bone mineral density in Malaysian women.
        Malays J Pathol. 2018; 40: 287-294
        • Eloi M.
        • Horvath D.V.
        • Ortega J.C.
        • Prado M.S.
        • Andrade L.E.
        • Szejnfeld V.L.
        • et al.
        25-Hydroxivitamin D serum concentration, not free and bioavailable vitamin D, is associated with disease activity in systemic lupus erythematosus patients.
        PloS One. 2017; 12: e0170323
        • Bandera Merchan B.
        • Morcillo S.
        • Martin-Nunez G.
        • Tinahones F.J.
        • Macias-Gonzalez M.
        The role of vitamin D and VDR in carcinogenesis: through epidemiology and basic sciences.
        J Steroid Biochem Mol Biol. 2017; 167: 203-218
        • Li M.
        • Chen P.
        • Li J.
        • Chu R.
        • Xi e D.
        • Wang H.
        Review: the impacts of circulating 25-hydroxyvitamin D levels on cancer patient outcomes: a systematic review and meta-analysis.
        J Clin Endocrinol Metab. 2014; 99: 2327-2336
        • Kim S.J.
        • Shu C.
        • Ryu K.J.
        • Kang D.
        • Cho J.
        • Ko Y.H.
        • et al.
        Vitamin D deficiency is associated with inferior survival of patients with extranodal natural killer/T-cell lymphoma.
        Canc Sci. 2018; 109: 3971-3980
        • Drake M.T.
        • Maurer M.J.
        • Link B.K.
        • Habermann T.M.
        • Ansell S.M.
        • Micallef I.N.
        • et al.
        Vitamin D insufficiency and prognosis in non-Hodgkin's lymphoma.
        J Clin Oncol. 2010; 28: 4191-4198
        • Pardanani A.
        • Drake M.T.
        • Finke C.
        • Lasho T.L.
        • Rozell S.A.
        • Jimma T.
        • et al.
        Vitamin D insufficiency in myeloproliferative neoplasms and myelodysplastic syndromes: clinical correlates and prognostic studies.
        Am J Hematol. 2011; 86: 1013-1016
        • Shanafelt T.D.
        • Drake M.T.
        • Maurer M.J.
        • Allmer C.
        • Rabe K.G.
        • Slager S.L.
        • et al.
        Vitamin D insufficiency and prognosis in chronic lymphocytic leukemia.
        Blood. 2011; 117: 1492-1498
        • Sabattini E.
        • Bacci F.
        • Sagramoso C.
        • Pileri S.A.
        WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview.
        Pathologica. 2010; 102: 83-87
        • Cheson B.D.
        The International Harmonization Project for response criteria in lymphoma clinical trials.
        Hematol Oncol Clin N Am. 2007; 21: 841-854
        • Nykjaer A.
        • Dragun D.
        • Walther D.
        • Vorum H.
        • Jacobsen C.
        • Herz J.
        • et al.
        An endocytic pathway essential for renal uptake and activation of the steroid 25-(OH) vitamin D3.
        Cell. 1999; 96: 507-515
        • Safadi F.F.
        • Thornton P.
        • Magiera H.
        • Hollis B.W.
        • Gentile M.
        • Haddad J.G.
        • et al.
        Osteopathy and resistance to vitamin D toxicity in mice null for vitamin D binding protein.
        J Clin Invest. 1999; 103: 239-251
        • Fang A.P.
        • Long J.A.
        • Zhang Y.J.
        • Liu Z.Y.
        • Li Q.J.
        • Zhang D.M.
        • et al.
        Serum bioavailable, rather than total, 25-hydroxyvitamin D levels are associated with hepatocellular carcinoma survival.
        Hepatology. 2019; ([Epub ahead of print])https://doi.org/10.1002/hep.31013
        • Theodoratou E.
        • Tzoulaki I.
        • Zgaga L.
        • Ioannidis J.P.
        Vitamin D and multiple health outcomes: umbrella review of systematic reviews and meta-analyses of observational studies and randomised trials.
        BMJ. 2014; 348: g2035
        • Chowdhury R.
        • Kunutsor S.
        • Vitezova A.
        • Oliver-Williams C.
        • Chowdhury S.
        • Kiefte-de-Jong J.C.
        • et al.
        Vitamin D and risk of cause specific death: systematic review and meta-analysis of observational cohort and randomised intervention studies.
        BMJ. 2014; 348: g1903
        • Bittenbring J.T.
        • Neumann F.
        • Altmann B.
        • Achenbach M.
        • Reichrath J.
        • Ziepert M.
        • et al.
        Vitamin D deficiency impairs rituximab-mediated cellular cytotoxicity and outcome of patients with diffuse large B-cell lymphoma treated with but not without rituximab.
        J Clin Oncol. 2014; 32: 3242-3248
        • Kelly J.L.
        • Friedberg J.W.
        • Calvi L.M.
        • van Wijngaarden E.
        • Fisher S.G.
        A case-control study of ultraviolet radiation exposure, vitamin D, and lymphoma risk in adults.
        Canc Causes Control. 2010; 21: 1265-1275
        • Purdue M.P.
        • Freedman D.M.
        • Gapstur S.M.
        • Helzlsouer K.J.
        • Laden F.
        • Lim U.
        • et al.
        Circulating 25-hydroxyvitamin D and risk of non-hodgkin lymphoma: cohort consortium vitamin D pooling Project of rarer cancers.
        Am J Epidemiol. 2010; 172: 58-69
        • Mikhak B.
        • Bracci P.M.
        • Gong Z.
        Intake of vitamins D and A and calcium and risk of non-Hodgkin lymphoma: San Francisco Bay Area population-based case-control study.
        Nutr Canc. 2012; 64: 674-684
        • Park H.Y.
        • Hong Y.C.
        • Lee K.
        • Koh J.
        Vitamin D status and risk of non-Hodgkin lymphoma: an updated meta-analysis.
        PloS One. 2019; 14 (e0216284)
        • Sehn L.H.
        • Berry B.
        • Chhanabhai M.
        • Fitzgerald C.
        • Gill K.
        • Hoskins P.
        • et al.
        The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP.
        Blood. 2007; 109: 1857-1861
        • Ochi Y.
        • Kazuma Y.
        • Hiramoto N.
        • Ono Y.
        • Yoshioka S.
        • Yonetani N.
        • et al.
        Utility of a simple prognostic stratification based on platelet counts and serum albumin levels in elderly patients with diffuse large B cell lymphoma.
        Ann Hematol. 2017; 96: 1-8
        • Wei Y.
        • Wei X.
        • Huang W.
        • Song J.
        • Zheng J.
        • Zeng H.
        • et al.
        Albumin improves stratification in the low IPI risk patients with diffuse large B-cell lymphoma.
        Int J Hematol. 2020; 111: 681-685
        • Jeon S.M.
        • Shin E.A.
        Exploring vitamin D metabolism and function in cancer.
        Exp Mol Med. 2018; 50: 20
        • Zhu Y.
        • Chen P.
        • Gao Y.
        • Ta N.
        • Zhang Y.
        • Cai J.
        • et al.
        MEG3 activated by vitamin D inhibits colorectal cancer cells proliferation and migration via regulating clusterin.
        EBioMedicine. 2018; 30: 148-157
        • Jiang Y.J.
        • Bikle D.D.
        LncRNA profiling reveals new mechanism for VDR protection against skin cancer formation.
        J Steroid Biochem Mol Biol. 2014; 144 Pt A: 87-90
        • Chen S.
        • Sims G.P.
        • Chen X.X.
        • Gu Y.Y.
        • Chen S.
        • Lipsky P.E.
        Modulatory effects of 1,25-dihydroxyvitamin D3 on human B cell differentiation.
        J Immunol. 2007; 179: 1634-1647
        • Hohaus S.
        • Tisi M.C.
        • Bellesi S.
        • Maiolo E.
        • Alma E.
        • Tartaglia G.
        • et al.
        Vitamin D deficiency and supplementation in patients with aggressive B-cell lymphomas treated with immunochemotherapy.
        Canc Med. 2018; 7: 270-281
        • Kozielewicz P.
        • Grafton G.
        • Kutner A.
        • Curnow S.J.
        • Gordon J.
        • Barnes N.M.
        Novel vitamin D analogues; cytotoxic and anti-proliferative activity against a diffuse large B-cell lymphoma cell line and B-cells from healthy donors.
        J Steroid Biochem Mol Biol. 2016; 164: 98-105